DrugPatentWatch Database Preview
Vertex Pharms Inc Company Profile
Email this page to a colleague
See Plans and PricingWhat is the competitive landscape for VERTEX PHARMS INC, and what generic alternatives to VERTEX PHARMS INC drugs are available?
VERTEX PHARMS INC has five approved drugs.
There are thirty-three US patents protecting VERTEX PHARMS INC drugs.
There are four hundred and seven patent family members on VERTEX PHARMS INC drugs in thirty-eight countries and thirty-two supplementary protection certificates in fifteen countries.
Summary for Vertex Pharms Inc
| International Patents: | 407 |
| US Patents: | 33 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Vertex Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-001 | Mar 17, 2015 | RX | Yes | No | 10,272,046 | Start Trial | Y | Start Trial | |||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-001 | Jul 2, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET, TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | 8,415,387 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Vertex Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| India | 2423KON2014 | Start Trial |
| Israel | 221827 | Start Trial |
| Russian Federation | 2525115 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1773816 | C 2015 027 | Romania | Start Trial | PRODUCT NAME: IVACAFTOR SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAN-(5-HIDROXI-2,4-DITERT-BUTIL-FENIL)-4-OXO-1H-CHINOLIN-3-CARBOXAMIDA SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/12/782/001, EU/1/12/782/002; DATE OF NATIONAL AUTHORISATION: 20120723; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/782/001, EU/1/12/782/002; DATE OF FIRST AUTHORISATION IN EEA: 20120723 |
| 1773816 | 1590036-8 | Sweden | Start Trial | PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/12/782/001 20120725 |
| 2225230 | 2017009 | Norway | Start Trial | PRODUCT NAME: 3-6-(1-(2,2-DIFLUOR-1,3-; REG. NO/DATE: EU/1/15/1059 20151210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
